APA (7th ed.) Citation

Chow, Y., Cheng, H., & Chen, M. Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer. Wolters Kluwer Medknow Publications.

Chicago Style (17th ed.) Citation

Chow, Yat-Fung, Hou-Hsuan Cheng, and Ming-Huang Chen. Durable Clinical Benefit After Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer. Wolters Kluwer Medknow Publications.

MLA (9th ed.) Citation

Chow, Yat-Fung, et al. Durable Clinical Benefit After Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer. Wolters Kluwer Medknow Publications.